The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Murdock Terry L since 2018.
This trader's CIK number is 1274071.
At the time of last reporting, Murdock Terry L was the Chief Operating Officer of G1 Therapeutics, Inc.. (stock ticker symbol GTHX).
Also see all insider trading activities at G1 Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | GTHX | 0 | $0 | 14,366 | $56,779 | 0 | $0 |
| 2023 | GTHX | 0 | $0 | 3,729 | $16,420 | 0 | $0 |
| 2022 | GTHX | 0 | $0 | 2,093 | $18,685 | 0 | $0 |
| 2018 | GTHX | 0 | $0 | 14,080 | $671,035 | 14,080 | $190,218 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-07-05 | GTHX | Sale | 2,475 | 2.51 | 6,207 |
| 2024-05-13 | GTHX | Sale | 8,151 | 4.79 | 39,035 |
| 2024-01-03 | GTHX | Sale | 3,019 | 3.12 | 9,416 |
| 2024-01-04 | GTHX | Sale | 721 | 2.94 | 2,121 |
| 2023-07-05 | GTHX | Sale | 1,361 | 2.45 | 3,339 |
| 2023-01-04 | GTHX | Sale | 1,639 | 5.58 | 9,139 |
| 2023-01-05 | GTHX | Sale | 729 | 5.41 | 3,942 |
| 2022-07-05 | GTHX | Sale | 648 | 5.17 | 3,351 |
| 2022-01-05 | GTHX | Sale | 1,445 | 10.61 | 15,334 |
| 2018-12-03 | GTHX | Option Ex | 3,523 | 13.51 | 47,595 |
| 2018-12-03 | GTHX | Sale | 3,523 | 38.54 | 135,779 |
| 2018-11-05 | GTHX | Option Ex | 3,519 | 13.51 | 47,541 |
| 2018-11-05 | GTHX | Sale | 3,519 | 41.53 | 146,129 |
| 2018-09-04 | GTHX | Option Ex | 3,519 | 13.51 | 47,541 |
| 2018-09-04 | GTHX | Sale | 3,519 | 59.98 | 211,066 |
| 2018-08-03 | GTHX | Option Ex | 3,519 | 13.51 | 47,541 |
| 2018-08-03 | GTHX | Sale | 3,519 | 50.60 | 178,061 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Murdock Terry L (Chief Operating Officer of G1 Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.